While some elements of Bernard Coulie’s first startup experience left a bad taste in his mouth, he still enjoyed having the opportunity to work on front-running technology — not what’s trendy at the time, but what’s going to be hot in the future. That’s what led him to Pliant Therapeutics.

We launched our editorial advisory board in 2011, and since then, members have been connecting us with execs you want to read about. Take this month’s cover feature, and how that connection came about.

In this edited transcript from our August 2021 executive virtual roundtable, perspectives on life science manufacturing and the supply chain are provided by three biopharma execs.

Sometimes there is opportunity for leaders who show up when others don’t, such as building a reputation one is proud to have precede them.

After working at Pfizer and being instrumental in the SpringWorks spinout, Lara Sullivan, M.D., is no stranger to building pharma companies. But getting to where she is today as CEO of Pyxis Therapeutics hasn’t come without its challenges.

The decision by J.P. Morgan to make the 2022 annual healthcare conference fully virtual, inspires reflection on the past and advocacy for the future, in this final blog by Rob Wright, retired chief editor, Life Science Leader.

In this outlook article with 15 biopharma CEOs, they talk about everything from trends to watch, to disruptive innovations to the effects and future of remote work on the industry.

Here’s what 10 biopharmaceutical finance experts have to say as they prepare for 2022 and beyond.

With the average daily dose of a biologic costing roughly 22 times more than a small molecule, it seems leaders in biopharma manufacturing have never faced a greater challenge. Here’s what 12 of those execs have to say as they look to 2022 and beyond.